The effect of dipyridamole on the pharmacokinetics of metformin.

Phase 4

Recruiting

• Conditions: geneesmiddeleninteractie; Drug interaction

• Registration Number: NL-OMON37582
• Lead Sponsor: niversitair Medisch Centrum Sint Radboud

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 18

Inclusion Criteria

- Age 18-50 years
- Written informed consent

Exclusion Criteria

- Smoking
- Hypertension (systolic blood pressure > 140 mmgHg and/or diastolic blood pressure > 90 mmHg)
- Diabetes Mellitus (fasting glucose > 7.0 mmol/L or random glucose > 11.0 mmol/L)
- History of any cardiovascular disease
- Concomitant use of medication
- Renal dysfunction (MDRD < 60 ml/min)
- ECG abnormalities, other than first grade AV-block or right bundle branch block

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The area under the curve of the metformin plasma concentration of metformin at<br /><br>t=0, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, and 10 hours after the intake of the<br /><br>seventh tablet of metformin and the Cmax.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>not applicable.</p><br>